Frequency, Severity, and Risk Factors of Recurrence of Disease Activity After Fingolimod Discontinuation in Patients With MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Therapeutic Advances in Neurological Disorders
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis
Ther Adv Neurol Disord 2023 Feb 01;16(xx)17562864221150312, N Cerdá-Fuertes, S Nagy, S Schaedelin, T Sinnecker, E Ruberte, A Papadopoulou, J Würfel, J Kuhle, Ö Yaldizli, L Kappos, T Derfuss, BF DécardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.